Perimenopause and blood tests: what to measure before blaming hormones

The question is not “which hormone is wrong”, but which result changes a decision. In perimenopause, FSH and estradiol can rise, fall and contradict each other within weeks. A single blood test can therefore falsely reassure or create unnecessary alarm. Useful assessment combines age, menstrual pattern, symptoms, cardiovascular risk, bone, metabolism, thyroid, iron and body composition.

This guide is the diagnostic hub for the Women’s Vital Path cluster. If you are still mapping symptoms, start with perimenopause symptoms. If memory, focus or mental overload is the main issue, read menopause brain fog. If the main issue is weight or abdominal fat, pair it with menopause weight gain. For the broader prevention map, review longevity biomarkers.

Why FSH and estradiol are not enough

Perimenopause is not a switch. STRAW+10 stages reproductive aging mainly from menstrual pattern, with biomarkers such as FSH as support, not as an oracle. In early transition cycles may shorten or vary; in late transition longer gaps appear. Meanwhile the ovaries may produce high estradiol peaks and low-estrogen weeks.

Mayo Clinic summarizes the practical point: there is no single test or symptom that tells you perimenopause has started; clinicians look at age, menstrual history and body changes. The important exception is excluding mimics, especially thyroid disease.

Test	What it can tell	Practical limits	When to order it
FSH	Persistently high values suggest lower ovarian reserve or advanced transition.	It fluctuates; contraception and high progestogens can invalidate it.	Age 40-45 with symptoms, suspected early menopause or POI.
Estradiol (E2)	Estrogen context at that moment.	One sample may be high or low without representing the whole month.	Specific treatment decisions, not as the sole diagnostic test.
AMH	Ovarian reserve in fertility care.	NICE does not recommend it to identify perimenopause/menopause in 45+.	Fertility/reproductive decisions, not to explain all symptoms.
Progesterone	May confirm ovulation if timed in the luteal phase.	A random value says little in irregular cycles.	Abnormal bleeding, fertility or specific clinical decisions.

FSH and estradiol: useful ranges without turning them into dogma

Ranges vary by lab, cycle phase and hormonal treatment. As clinical orientation:

Marker	Common orientation	Safe interpretation
FSH <10 IU/L	Common in reproductive years.	Does not exclude perimenopause if symptoms and cycles are changing.
FSH 10-25 IU/L	Variable zone.	May appear in transition; repeat only if it changes action.
FSH >25-30 IU/L	Compatible with advanced transition or menopause depending on context.	More useful with amenorrhea/cycle change and no external hormones.
Estradiol 30-400 pg/mL	May be normal depending on cycle phase.	A “normal” value does not invalidate symptoms in perimenopause.
Estradiol <20-30 pg/mL	Compatible with low-estrogen/postmenopausal state.	Confirm with clinical history; do not treat the number alone.

Key message: if you are 47 with irregular cycles, hot flashes and broken sleep, an FSH that is “not high” does not cancel the picture. If you are 42 with amenorrhea, hot flashes or infertility, that is when deeper evaluation matters.

The labs that do change decisions

Perimenopause can coexist with thyroid disease, low iron, low B12, insulin resistance, high ApoB, inflammation or muscle loss. Useful testing therefore goes beyond the ovarian axis.

Area	What to measure	Why it matters	Decision it changes
Thyroid	TSH, free T4; TPO/Tg antibodies if autoimmune suspicion.	Fatigue, cold intolerance, hair loss, low mood and weight change can mimic menopause.	Treat real hypothyroidism before blaming sex hormones.
Iron	CBC, ferritin, transferrin saturation when relevant.	Irregular heavy bleeding can lower iron and cause fatigue, palpitations or brain fog.	Investigate bleeding, supplement and adjust training.
B12/folate	B12, folate; homocysteine/MMA if uncertain.	Fatigue, paresthesia and cognition can be misread as “hormones”.	Correct deficiency and review diet, metformin or acid blockers.
Vitamin D/bone	25-OH vitamin D, calcium, PTH if indicated; DEXA by risk.	The transition accelerates bone loss; pain is not always muscle.	Strength, protein, calcium, vitamin D or osteoporosis workup.
Glucose/insulin	Glucose, HbA1c, fasting insulin, HOMA-IR.	Insulin resistance may rise with visceral fat and poor sleep.	Nutrition, strength, fat-loss strategy and cardiometabolic follow-up.
Lipids	ApoB, LDL-C, HDL-C, triglycerides, one-time Lp(a).	Vascular risk is reconfigured after menopause.	Do not reduce the plan to hot flashes: prioritize cardiovascular prevention.
Inflammation	hsCRP; ESR/autoantibodies if symptoms fit.	Joint pain, fatigue or prolonged stiffness are not always menopause.	Refer or rule out inflammatory disease when there are signs.
Safety baseline	ALT/AST, GGT, creatinine/eGFR, blood pressure.	Safety before treatment, supplements or medication.	Choose dose, hormonal route, drugs or restrictions.

By dominant symptom: what to prioritize

Main symptom	Priority labs	Why	Do not forget
Hot flashes/night sweats	Clinical diagnosis; FSH only if age/scenario requires it.	Treatment is decided from symptoms, risk and preferences.	Review sleep, alcohol, medication and contraindications.
Fatigue and brain fog	CBC, ferritin, B12, TSH/free T4, glucose/HbA1c.	Avoid attributing iron, thyroid or metabolism to estradiol.	Brain fog should always be cross-checked with sleep, iron, B12, thyroid and glucose.
Weight/waist gain	Insulin, HbA1c, ApoB, triglycerides, body composition.	The goal is visceral fat and muscle, not scale weight alone.	See menopause weight gain.
Joint pain	Vitamin D, hsCRP, TSH, glucose; autoantibodies if long stiffness/inflammation.	Pain and stiffness have a differential diagnosis.	Progressive strength and physiotherapy if tendon/shoulder pattern.
Heavy bleeding	CBC, ferritin and gynecologic evaluation.	Anemia can explain fatigue and palpitations.	Postmenopausal bleeding always needs evaluation.

What not to order by default

• Monthly hormone panels without a clinical question. Many numbers, few decisions.
• Single cortisol “for stress”. Useful in specific scenarios, but not a standalone explanation for perimenopause.
• Testosterone without symptoms or reliable method. Measurement in women needs method and context; do not chase a number for “energy”.
• Expensive fertility markers to diagnose menopause in 45+. AMH does not replace clinical history.
• Aggressive supplementation without deficiency. Iron, D, B12 or iodine should not be used as a lottery.

When deeper evaluation is needed

• No periods or menopause-like symptoms before age 40.
• Symptoms between 40 and 45 with cycle change.
• Very heavy bleeding, bleeding between periods or bleeding after 12 months without a period.
• Unexplained weight loss, fever, prolonged joint stiffness, chest pain, shortness of breath or intense palpitations.
• Hormonal contraception, hormonal IUD, uterine surgery or ovarian history that makes cycles hard to interpret.
• Strong family history of early cardiovascular disease, osteoporosis or thrombosis.

How Progevita does it

In Women’s Vital Path, lab work is not a collection of tests; it is a decision tool. Dr Lorena Vela and the team interpret symptoms, cycle, medical history, body composition, sleep, vascular risk, bone and lifestyle before proposing hormone therapy, nutrition, strength, supplementation or follow-up.

The aim is not to “blame hormones”. It is to separate hormonal, metabolic, thyroid, inflammatory and trainable components. That is how we avoid hormone noise: lots of laboratory language, little medicine.

Conclusion

The best blood work for perimenopause is not the longest panel; it is the one that prevents mistakes: diagnosing from one FSH, ignoring thyroid or iron, reducing cardiometabolic risk to aesthetics, or starting treatments without context. In women aged 45+ with typical symptoms, diagnosis usually starts clinically; precision comes from measuring what changes the plan.

Sources

1. NICE. Menopause: identification and management NG23, recommendations updated 2024. NICE NG23.
2. Harlow SD et al. Executive summary of STRAW+10. Menopause. 2012. PMID: 22343510.
3. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022. PMID: 35797481.
4. El Khoudary SR et al. Menopause transition and cardiovascular disease risk: AHA scientific statement. Circulation. 2020. PMID: 33251828.
5. Berent-Spillson A et al. Hormonal environment affects cognition during the menopause transition. J Clin Endocrinol Metab. 2012. PMID: 22730514.
6. Papadakis GE et al. Menopausal hormone therapy and visceral adiposity: OsteoLaus. J Clin Endocrinol Metab. 2018. PMID: 29596606.
7. Mayo Clinic. Perimenopause - Diagnosis and treatment. Mayo Clinic.
8. Cleveland Clinic. Perimenopause: age, stages, signs, symptoms & treatment. Cleveland Clinic.

This content is educational and does not replace individual medical assessment. Ranges vary by lab, age, cycle phase, medication and clinical context.